Last reviewed · How we verify
Experimental for antifungals
This experimental antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation.
This experimental antifungal drug inhibits fungal cell wall or membrane synthesis to prevent fungal growth and proliferation. Used for Invasive fungal infections (specific indication under Phase 3 evaluation).
At a glance
| Generic name | Experimental for antifungals |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
While the specific molecular target is not publicly disclosed, antifungals in development typically work by disrupting ergosterol synthesis, inhibiting β-glucan synthase, or targeting other fungal-specific biosynthetic pathways. This Phase 3 candidate from AP-HP is being evaluated for efficacy and safety in treating systemic or invasive fungal infections.
Approved indications
- Invasive fungal infections (specific indication under Phase 3 evaluation)
Common side effects
Key clinical trials
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. (PHASE3)
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)
- Protocol for Improvement of Therapy With Warfarin (PHASE3)
- CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia (PHASE1, PHASE2)
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (PHASE3)
- A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease (PHASE4)
- Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental for antifungals CI brief — competitive landscape report
- Experimental for antifungals updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI